View ValuationSinopharm Group 향후 성장Future 기준 점검 1/6Sinopharm Group (는) 각각 연간 9% 및 4.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 9.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9% 로 예상됩니다.핵심 정보9.0%이익 성장률9.83%EPS 성장률Healthcare 이익 성장19.0%매출 성장률4.9%향후 자기자본이익률8.97%애널리스트 커버리지Good마지막 업데이트28 Apr 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 10Sinopharm Group Co. Ltd. to Report Q1, 2026 Results on Apr 24, 2026Sinopharm Group Co. Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026공시 • Mar 23Sinopharm Group Co. Ltd., Annual General Meeting, Jun 18, 2026Sinopharm Group Co. Ltd., Annual General Meeting, Jun 18, 2026.공시 • Mar 10Sinopharm Group Co. Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026Sinopharm Group Co. Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026공시 • Nov 28Sinopharm Group Co. Ltd. Announces Board and Committee ResignationsThe board of directors of Sinopharm Group Co. Ltd. announced that on 28 November 2025, due to the work arrangement, Mr. Zhao Bingxiang ("Mr. Zhao") tendered his resignation to the Board as a non-executive Director, the chairman (the "Chairman") of the Board, the chairman of the nomination committee of the Board (the "Nomination Committee"), the chairman of the strategy and investment committee of the Board (the "Strategy and Investment Committee"), a member of the legal and compliance and environmental, social and governance committee of the Board (the "Legal and Compliance and Environmental, Social and Governance Committee") and the authorized representative (the "Authorized Representative") of the Company (pursuant to Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")), and Ms. Feng Rongli ("Ms. Feng") tendered her resignation to the Board as a non-executive Director, a member of the remuneration committee of the Board and a member of the Nomination Committee. Each of the above resignations shall take effect from the appointment of their respective replacement at the general meeting of the Company.공시 • Oct 10Sinopharm Group Co. Ltd. to Report Nine Months, 2025 Results on Oct 24, 2025Sinopharm Group Co. Ltd. announced that they will report nine months, 2025 results on Oct 24, 2025공시 • Aug 12Sinopharm Group Co. Ltd. to Report First Half, 2025 Results on Aug 22, 2025Sinopharm Group Co. Ltd. announced that they will report first half, 2025 results on Aug 22, 2025공시 • Jun 12+ 1 more updateSinopharm Group Co. Ltd. Approves Final Ordinary Cash Dividend for the Year Ended 31 December 2024, Payable No Later Than 12 August 2025Sinopharm Group Co. Ltd. at its AGM held on June 12, 2025 approved final ordinary cash dividend of RMB 0.68 per share (inclusive of tax) for the year ended 31 December 2024. The Final Dividend will be paid no later than 12 August 2025 to the Shareholders whose names appear on the register of members of the Company on 23 June 2025. Ex-dividend date of 16 June 2025.공시 • Apr 10Sinopharm Group Co. Ltd. to Report Q1, 2025 Results on Apr 25, 2025Sinopharm Group Co. Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025공시 • Mar 24+ 1 more updateSinopharm Group Co. Ltd. Proposes Distribution of Final Dividend for the Financial Year End 31 December 2024, Payable on 12 August 2025Sinopharm Group Co. Ltd. proposed distribution of final dividend for the financial year end 31 December 2024 of RMB 0.68 per share. Date of shareholders' approval: 12 June 2025. Ex-dividend date: 16 June 2025; Record date: 23 June 2025; Payment date: 12 August 2025.공시 • Mar 12Sinopharm Group Co. Ltd. to Report Fiscal Year 2024 Results on Mar 21, 2025Sinopharm Group Co. Ltd. announced that they will report fiscal year 2024 results on Mar 21, 2025공시 • Feb 12Sinopharm Group Co. Ltd. Approves Board AppointmentsSinopharm Group Co. Ltd. announced at its EGM held on February 12, 2025, the shareholders approved appointment of Mr. Sun Jinglin as an executive Director of the sixth session of the Board; Mr. Hu Ligang as a non-executive Director of the sixth session of the Board; Mr. Zu Jing as a non-executive Director of the sixth session of the Board; and Mr. Xing Yonggang as a non-executive Director of the sixth session of the Board.공시 • Jan 08Sinopharm Group Co. Ltd. Announces Board ResignationsSinopharm Group Co. Ltd. announced that, due to work needs, Mr. Wang Kan and Mr. Wang Peng have tendered their resignation as non-executive directors to the board on 8 January 2025. The resignations will take immediate effect.공시 • Oct 14Sinopharm Group Co. Ltd. to Report Nine Months, 2024 Results on Oct 25, 2024Sinopharm Group Co. Ltd. announced that they will report nine months, 2024 results on Oct 25, 2024공시 • Aug 28Sinopharm Group Co. Ltd. Announces Change in PresidentThe Board of Sinopharm Group Co. Ltd. announced that it resolved to appoint Mr. Lian Wanyong as the President of the Company on 27 August 2024 with immediate effect. Mr. Liu Yong ("Mr. Liu") ceased to be the President. The above arrangements took effect immediately. Mr. Lian Wanyong, aged 53, holds a master's degree in medicine from Zhongshan Medical Sciences University and a master's degree in business administration from the University of Miami and is an associate chief pharmacist. Mr. Lian successively served as the deputy director of the financial assets management department, a director of the investment management department and the deputy director of policy research office of China National Pharmaceutical Group Co. Ltd. Mr. Lian successively served as a Director and supervisor of the Company from December 2008 to January 2018, and served as a vice president and a member of Party Committee of the Company, a director of China National Accord Medicines Corporation Ltd. and a director of China National Medicines Corporation Ltd. from January 2018 to September 2022. Mr. Lian served as a director, the president and the deputy secretary of Party Committee of Shanghai Shyndec Pharmaceutical Co. Ltd. from September 2022 to August 2024.공시 • Aug 27Sinopharm Group Co. Ltd. Announces Management ChangesThe board of directors of Sinopharm Group Co. Ltd. announced that it resolved to propose to appoint Mr. Zhao Bingxiang ("Mr. Zhao") as the non-executive Director and Mr. Lian Wanyong ("Mr. Lian") as the executive Director (the "Proposed Appointment of Directors") on 27 August 2024. In accordance with the articles of association of the Company (the "Articles of Association"), the above Proposed Appointment of Directors are subject to the approval by the shareholders of the Company (the "Shareholders") at the extraordinary general meeting of the Company. The Board hereby announces that it resolved to appoint Mr. Lian Wanyong as the President of the Company on 27 August 2024 with immediate effect. The Board hereby announces that on 27 August 2024, due to work needs, Mr. Yu Qingming ("Mr. Yu") ceased to be the Chairman of the Board, an executive Director as well as the chairman of the Nomination Committee, the chairman of the strategy and investment committee of the Board (the "Strategy and Investment Committee") and a member of the legal and compliance and environmental, social and governance committee of the Board (the "Legal and Compliance and Environmental, Social and Governance Committee"); Mr. Liu Yong ("Mr. Liu") ceased to be an executive Director, the President and a member of the Strategy and Investment Committee and a member of the Legal and Compliance and Environmental, Social and Governance Committee. The above arrangements took effect immediately. China National Pharmaceutical Group Co. Ltd. will make other appointments for Mr. Yu and Mr. Liu. Mr. Lian Wanyong, aged 53, holds a master's degree in medicine from Zhongshan Medical Sciences University and a master's degree in business administration from the University of Miami and is an associate chief pharmacist. Mr. Lian successively served as the deputy director of the financial assets management department, a director of the investment management department and the deputy director of policy research office of China National Pharmaceutical Group Co. Ltd. Mr. Lian successively served as a Director and supervisor of the Company from December 2008 to January 2018, and served as a vice president and a member of Party Committee of the Company, a director of China National Accord Medicines Corporation Ltd. and a director of China National Medicines Corporation Ltd. from January 2018 to September 2022. Mr. Lian served as a director, the president and the deputy secretary of Party Committee of Shanghai Shyndec Pharmaceutical Co. Ltd. from September 2022 to August 2024.공시 • Aug 09Sinopharm Group Co. Ltd. to Report First Half, 2024 Results on Aug 23, 2024Sinopharm Group Co. Ltd. announced that they will report first half, 2024 results on Aug 23, 2024공시 • Jun 14Sinopharm Group Co. Ltd. Declares Final Dividend for the Fiscal Year Ended December 31, 2023, Payable on 13 August 2024Sinopharm Group Co. Ltd. declared final dividend of RMB 0.87 per share for the fiscal year ended December 31, 2023. Ex-dividend date is 17 June 2024. Record date is 24 June 2024Payment date is 13 August 2024.공시 • Apr 17Sinopharm Group Co. Ltd. to Report Q1, 2024 Results on Apr 26, 2024Sinopharm Group Co. Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024공시 • Mar 13Sinopharm Group Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024Sinopharm Group Co. Ltd. announced that they will report fiscal year 2023 results on Mar 22, 2024공시 • Oct 14Sinopharm Group Co. Ltd. to Report Nine Months, 2023 Results on Oct 27, 2023Sinopharm Group Co. Ltd. announced that they will report nine months, 2023 results on Oct 27, 2023공시 • Sep 16Sinopharm Group Co. Ltd. Approves Appointment of Guo Jinhong as Chief SupervisorSinopharm Group Co. Ltd. at its EGM held on September 15, 2023, considered and approved (if thought fit) the appointment of Mr. Guo Jinhong as a shareholder representative Supervisor of the sixth session of the Supervisory Committee, to authorize the Supervisory Committee to determine his remuneration and to authorize the chairman of the Board or any executive Director to enter into the service contract or such other documents or supplemental agreements or deeds with him. The Board also announced that the sixth session of the Supervisory Committee comprises five Supervisors, and the independent Supervisors are Ms. Guan Xiaohui and Mr. Liu Zhengdong, shareholderrepresentative Supervisor is Mr. Guo Jinhong and the employee representative Supervisors are Mr. Liu Hongbing and Ms. Lu Haiqing. The first meeting of the sixth session of the Supervisory Committee was held on 15 September 2023 and resolved to elect Ms. Guan Xiaohui as the chief Supervisor of the Supervisory Committee.공시 • Aug 29Sinopharm Group Co. Ltd. Announces Retirement of Ma Ping, A Non-Executive DirectorSinopharm Group Co. Ltd. announced meanwhile, in view of the retirement of Mr. Ma Ping, a non-executive Director, the Board resolved at the same meeting to propose to appoint Mr. Wang Peng as a non-executive Director of the sixth session of the Board. The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect. Mr. Ma Ping, a non-executive Director of the fifth session of the Board, will retire upon the approval of appointment of Directors of the sixth session of the Board at the extraordinary general meeting of the Company. Mr. Ma Ping has confirmed that he has no disagreement with the Board, and there is no other matters relating to his resignation as a Director that needs to be brought to the attention of the shareholders (the "Shareholders") and creditors of the Company. The Board would like to take this opportunity to express its sincere gratitude to Mr. Ma Ping for his contributions to the Company during his tenure as a Director. The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect.공시 • Aug 16Sinopharm Group Co. Ltd. to Report First Half, 2023 Results on Aug 25, 2023Sinopharm Group Co. Ltd. announced that they will report first half, 2023 results on Aug 25, 2023공시 • Jun 16+ 1 more updateSinopharm Group Co. Ltd. Approves Final Dividend for the Financial Year End 31 December 2022, Payable on 14 August 2023Sinopharm Group Co. Ltd. approves final dividend of RMB 0.82 per share for the financial year end 31 December 2022, payable on 14 August 2023. Ex-dividend date 19 June 2023 and Record date 26 June 2023.공시 • May 19Sinopharm Group Co. Ltd. Announces Resignation of Zhuo Fumin as Independent Non-Executive DirectorSinopharm Group Co. Ltd. (the Company) announced that on 18 May 2023, due to attainment of the term of service of independent non-executive Directors as stipulated in the Rules of Procedure of Board of Directors of the Company, Mr. Zhuo Fumin (Mr. Zhuo) tendered his resignation as an independent non-executive Director of the Company, a member of the audit committee of the Board (the Audit Committee), and a member of the nomination committee of the Board (the Nomination Committee), which shall take effect from the appointment of his replacement at the general meeting of the Company. Mr. Zhuo has confirmed that he has no disagreement with the Board and there is no other matters relating to his resignation as a Director that needs to be brought to the attention of the shareholders of the Company (the Shareholders) and creditors of the Company.이익 및 매출 성장 예측OTCPK:SHTD.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028657,4819,14612,60115,270912/31/2027622,5508,3809,96213,2271312/31/2026590,6207,71115,24014,501113/31/2026574,2727,11214,60916,246N/A12/31/2025575,1687,15512,53514,138N/A9/30/2025573,5647,07818,69620,187N/A6/30/2025575,8246,81117,32518,429N/A3/31/2025578,9047,08723,16524,752N/A12/31/2024584,5087,0509,80811,546N/A9/30/2024593,0738,236-33,041-29,421N/A6/30/2024590,3468,65316,76819,506N/A3/31/2024598,3188,8848,03510,385N/A12/31/2023596,5709,05414,88917,173N/A9/30/2023591,6868,76519,02721,349N/A6/30/2023591,6268,9369,66011,931N/A3/31/2023570,0678,68814,30216,763N/A12/31/2022552,1488,52618,64820,964N/A9/30/2022546,1477,91437,50938,425N/A6/30/2022533,4037,8704922,783N/A3/31/2022528,3837,9705,3787,658N/A12/31/2021521,0517,7597,0819,308N/A9/30/2021510,0917,9304,5116,795N/A6/30/2021501,7707,8748,74310,983N/A3/31/2021474,7986,956-12,001-9,890N/A12/31/2020456,4157,1879,09911,155N/A9/30/2020440,1946,6155,9988,075N/A6/30/2020427,3726,1742,3044,522N/A3/31/2020431,9766,55424,34426,653N/A12/31/2019425,2736,251N/A18,777N/A9/30/2019406,3946,311N/A2,113N/A6/30/2019382,7176,012N/A1,744N/A3/31/2019360,7606,087N/A-3,011N/A12/31/2018344,5265,834N/A3,654N/A9/30/2018336,1135,523N/A-6,868N/A6/30/2018334,0605,606N/A2,882N/A3/31/2018318,4145,083N/A-6,249N/A12/31/2017308,3545,572N/A3,209N/A9/30/2017288,8555,217N/A-19N/A6/30/2017269,3564,861N/A-3,247N/A3/31/2017264,6914,996N/AN/AN/A12/31/2016258,3884,635N/A9,258N/A9/30/2016251,4014,515N/A11,117N/A6/30/2016244,4144,394N/A12,975N/A3/31/2016234,4993,885N/AN/AN/A12/31/2015228,6733,772N/A13,412N/A9/30/2015222,5133,548N/A9,472N/A6/30/2015216,3533,323N/A5,533N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: SHTD.F 의 연간 예상 수익 증가율(9%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: SHTD.F 의 연간 수익(9%)이 US 시장(17.1%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: SHTD.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: SHTD.F 의 수익(연간 4.9%)이 US 시장(연간 11.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: SHTD.F 의 수익(연간 4.9%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: SHTD.F의 자본 수익률은 3년 후 9%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/10 21:55종가2026/05/22 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sinopharm Group Co. Ltd.는 31명의 분석가가 다루고 있습니다. 이 중 13명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jason MannBarclaysBo LiBofA Global ResearchXiwan JinCCB International Securities Limited28명의 분석가 더 보기
공시 • Apr 10Sinopharm Group Co. Ltd. to Report Q1, 2026 Results on Apr 24, 2026Sinopharm Group Co. Ltd. announced that they will report Q1, 2026 results on Apr 24, 2026
공시 • Mar 23Sinopharm Group Co. Ltd., Annual General Meeting, Jun 18, 2026Sinopharm Group Co. Ltd., Annual General Meeting, Jun 18, 2026.
공시 • Mar 10Sinopharm Group Co. Ltd. to Report Fiscal Year 2025 Results on Mar 20, 2026Sinopharm Group Co. Ltd. announced that they will report fiscal year 2025 results on Mar 20, 2026
공시 • Nov 28Sinopharm Group Co. Ltd. Announces Board and Committee ResignationsThe board of directors of Sinopharm Group Co. Ltd. announced that on 28 November 2025, due to the work arrangement, Mr. Zhao Bingxiang ("Mr. Zhao") tendered his resignation to the Board as a non-executive Director, the chairman (the "Chairman") of the Board, the chairman of the nomination committee of the Board (the "Nomination Committee"), the chairman of the strategy and investment committee of the Board (the "Strategy and Investment Committee"), a member of the legal and compliance and environmental, social and governance committee of the Board (the "Legal and Compliance and Environmental, Social and Governance Committee") and the authorized representative (the "Authorized Representative") of the Company (pursuant to Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")), and Ms. Feng Rongli ("Ms. Feng") tendered her resignation to the Board as a non-executive Director, a member of the remuneration committee of the Board and a member of the Nomination Committee. Each of the above resignations shall take effect from the appointment of their respective replacement at the general meeting of the Company.
공시 • Oct 10Sinopharm Group Co. Ltd. to Report Nine Months, 2025 Results on Oct 24, 2025Sinopharm Group Co. Ltd. announced that they will report nine months, 2025 results on Oct 24, 2025
공시 • Aug 12Sinopharm Group Co. Ltd. to Report First Half, 2025 Results on Aug 22, 2025Sinopharm Group Co. Ltd. announced that they will report first half, 2025 results on Aug 22, 2025
공시 • Jun 12+ 1 more updateSinopharm Group Co. Ltd. Approves Final Ordinary Cash Dividend for the Year Ended 31 December 2024, Payable No Later Than 12 August 2025Sinopharm Group Co. Ltd. at its AGM held on June 12, 2025 approved final ordinary cash dividend of RMB 0.68 per share (inclusive of tax) for the year ended 31 December 2024. The Final Dividend will be paid no later than 12 August 2025 to the Shareholders whose names appear on the register of members of the Company on 23 June 2025. Ex-dividend date of 16 June 2025.
공시 • Apr 10Sinopharm Group Co. Ltd. to Report Q1, 2025 Results on Apr 25, 2025Sinopharm Group Co. Ltd. announced that they will report Q1, 2025 results on Apr 25, 2025
공시 • Mar 24+ 1 more updateSinopharm Group Co. Ltd. Proposes Distribution of Final Dividend for the Financial Year End 31 December 2024, Payable on 12 August 2025Sinopharm Group Co. Ltd. proposed distribution of final dividend for the financial year end 31 December 2024 of RMB 0.68 per share. Date of shareholders' approval: 12 June 2025. Ex-dividend date: 16 June 2025; Record date: 23 June 2025; Payment date: 12 August 2025.
공시 • Mar 12Sinopharm Group Co. Ltd. to Report Fiscal Year 2024 Results on Mar 21, 2025Sinopharm Group Co. Ltd. announced that they will report fiscal year 2024 results on Mar 21, 2025
공시 • Feb 12Sinopharm Group Co. Ltd. Approves Board AppointmentsSinopharm Group Co. Ltd. announced at its EGM held on February 12, 2025, the shareholders approved appointment of Mr. Sun Jinglin as an executive Director of the sixth session of the Board; Mr. Hu Ligang as a non-executive Director of the sixth session of the Board; Mr. Zu Jing as a non-executive Director of the sixth session of the Board; and Mr. Xing Yonggang as a non-executive Director of the sixth session of the Board.
공시 • Jan 08Sinopharm Group Co. Ltd. Announces Board ResignationsSinopharm Group Co. Ltd. announced that, due to work needs, Mr. Wang Kan and Mr. Wang Peng have tendered their resignation as non-executive directors to the board on 8 January 2025. The resignations will take immediate effect.
공시 • Oct 14Sinopharm Group Co. Ltd. to Report Nine Months, 2024 Results on Oct 25, 2024Sinopharm Group Co. Ltd. announced that they will report nine months, 2024 results on Oct 25, 2024
공시 • Aug 28Sinopharm Group Co. Ltd. Announces Change in PresidentThe Board of Sinopharm Group Co. Ltd. announced that it resolved to appoint Mr. Lian Wanyong as the President of the Company on 27 August 2024 with immediate effect. Mr. Liu Yong ("Mr. Liu") ceased to be the President. The above arrangements took effect immediately. Mr. Lian Wanyong, aged 53, holds a master's degree in medicine from Zhongshan Medical Sciences University and a master's degree in business administration from the University of Miami and is an associate chief pharmacist. Mr. Lian successively served as the deputy director of the financial assets management department, a director of the investment management department and the deputy director of policy research office of China National Pharmaceutical Group Co. Ltd. Mr. Lian successively served as a Director and supervisor of the Company from December 2008 to January 2018, and served as a vice president and a member of Party Committee of the Company, a director of China National Accord Medicines Corporation Ltd. and a director of China National Medicines Corporation Ltd. from January 2018 to September 2022. Mr. Lian served as a director, the president and the deputy secretary of Party Committee of Shanghai Shyndec Pharmaceutical Co. Ltd. from September 2022 to August 2024.
공시 • Aug 27Sinopharm Group Co. Ltd. Announces Management ChangesThe board of directors of Sinopharm Group Co. Ltd. announced that it resolved to propose to appoint Mr. Zhao Bingxiang ("Mr. Zhao") as the non-executive Director and Mr. Lian Wanyong ("Mr. Lian") as the executive Director (the "Proposed Appointment of Directors") on 27 August 2024. In accordance with the articles of association of the Company (the "Articles of Association"), the above Proposed Appointment of Directors are subject to the approval by the shareholders of the Company (the "Shareholders") at the extraordinary general meeting of the Company. The Board hereby announces that it resolved to appoint Mr. Lian Wanyong as the President of the Company on 27 August 2024 with immediate effect. The Board hereby announces that on 27 August 2024, due to work needs, Mr. Yu Qingming ("Mr. Yu") ceased to be the Chairman of the Board, an executive Director as well as the chairman of the Nomination Committee, the chairman of the strategy and investment committee of the Board (the "Strategy and Investment Committee") and a member of the legal and compliance and environmental, social and governance committee of the Board (the "Legal and Compliance and Environmental, Social and Governance Committee"); Mr. Liu Yong ("Mr. Liu") ceased to be an executive Director, the President and a member of the Strategy and Investment Committee and a member of the Legal and Compliance and Environmental, Social and Governance Committee. The above arrangements took effect immediately. China National Pharmaceutical Group Co. Ltd. will make other appointments for Mr. Yu and Mr. Liu. Mr. Lian Wanyong, aged 53, holds a master's degree in medicine from Zhongshan Medical Sciences University and a master's degree in business administration from the University of Miami and is an associate chief pharmacist. Mr. Lian successively served as the deputy director of the financial assets management department, a director of the investment management department and the deputy director of policy research office of China National Pharmaceutical Group Co. Ltd. Mr. Lian successively served as a Director and supervisor of the Company from December 2008 to January 2018, and served as a vice president and a member of Party Committee of the Company, a director of China National Accord Medicines Corporation Ltd. and a director of China National Medicines Corporation Ltd. from January 2018 to September 2022. Mr. Lian served as a director, the president and the deputy secretary of Party Committee of Shanghai Shyndec Pharmaceutical Co. Ltd. from September 2022 to August 2024.
공시 • Aug 09Sinopharm Group Co. Ltd. to Report First Half, 2024 Results on Aug 23, 2024Sinopharm Group Co. Ltd. announced that they will report first half, 2024 results on Aug 23, 2024
공시 • Jun 14Sinopharm Group Co. Ltd. Declares Final Dividend for the Fiscal Year Ended December 31, 2023, Payable on 13 August 2024Sinopharm Group Co. Ltd. declared final dividend of RMB 0.87 per share for the fiscal year ended December 31, 2023. Ex-dividend date is 17 June 2024. Record date is 24 June 2024Payment date is 13 August 2024.
공시 • Apr 17Sinopharm Group Co. Ltd. to Report Q1, 2024 Results on Apr 26, 2024Sinopharm Group Co. Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024
공시 • Mar 13Sinopharm Group Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024Sinopharm Group Co. Ltd. announced that they will report fiscal year 2023 results on Mar 22, 2024
공시 • Oct 14Sinopharm Group Co. Ltd. to Report Nine Months, 2023 Results on Oct 27, 2023Sinopharm Group Co. Ltd. announced that they will report nine months, 2023 results on Oct 27, 2023
공시 • Sep 16Sinopharm Group Co. Ltd. Approves Appointment of Guo Jinhong as Chief SupervisorSinopharm Group Co. Ltd. at its EGM held on September 15, 2023, considered and approved (if thought fit) the appointment of Mr. Guo Jinhong as a shareholder representative Supervisor of the sixth session of the Supervisory Committee, to authorize the Supervisory Committee to determine his remuneration and to authorize the chairman of the Board or any executive Director to enter into the service contract or such other documents or supplemental agreements or deeds with him. The Board also announced that the sixth session of the Supervisory Committee comprises five Supervisors, and the independent Supervisors are Ms. Guan Xiaohui and Mr. Liu Zhengdong, shareholderrepresentative Supervisor is Mr. Guo Jinhong and the employee representative Supervisors are Mr. Liu Hongbing and Ms. Lu Haiqing. The first meeting of the sixth session of the Supervisory Committee was held on 15 September 2023 and resolved to elect Ms. Guan Xiaohui as the chief Supervisor of the Supervisory Committee.
공시 • Aug 29Sinopharm Group Co. Ltd. Announces Retirement of Ma Ping, A Non-Executive DirectorSinopharm Group Co. Ltd. announced meanwhile, in view of the retirement of Mr. Ma Ping, a non-executive Director, the Board resolved at the same meeting to propose to appoint Mr. Wang Peng as a non-executive Director of the sixth session of the Board. The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect. Mr. Ma Ping, a non-executive Director of the fifth session of the Board, will retire upon the approval of appointment of Directors of the sixth session of the Board at the extraordinary general meeting of the Company. Mr. Ma Ping has confirmed that he has no disagreement with the Board, and there is no other matters relating to his resignation as a Director that needs to be brought to the attention of the shareholders (the "Shareholders") and creditors of the Company. The Board would like to take this opportunity to express its sincere gratitude to Mr. Ma Ping for his contributions to the Company during his tenure as a Director. The Board resolved at the meeting of the Board held on 25 August 2023 to elect Mr. Shi Shenghao, an independent non-executive Director, as a member of the strategy and investment committee of the Board, with immediate effect.
공시 • Aug 16Sinopharm Group Co. Ltd. to Report First Half, 2023 Results on Aug 25, 2023Sinopharm Group Co. Ltd. announced that they will report first half, 2023 results on Aug 25, 2023
공시 • Jun 16+ 1 more updateSinopharm Group Co. Ltd. Approves Final Dividend for the Financial Year End 31 December 2022, Payable on 14 August 2023Sinopharm Group Co. Ltd. approves final dividend of RMB 0.82 per share for the financial year end 31 December 2022, payable on 14 August 2023. Ex-dividend date 19 June 2023 and Record date 26 June 2023.
공시 • May 19Sinopharm Group Co. Ltd. Announces Resignation of Zhuo Fumin as Independent Non-Executive DirectorSinopharm Group Co. Ltd. (the Company) announced that on 18 May 2023, due to attainment of the term of service of independent non-executive Directors as stipulated in the Rules of Procedure of Board of Directors of the Company, Mr. Zhuo Fumin (Mr. Zhuo) tendered his resignation as an independent non-executive Director of the Company, a member of the audit committee of the Board (the Audit Committee), and a member of the nomination committee of the Board (the Nomination Committee), which shall take effect from the appointment of his replacement at the general meeting of the Company. Mr. Zhuo has confirmed that he has no disagreement with the Board and there is no other matters relating to his resignation as a Director that needs to be brought to the attention of the shareholders of the Company (the Shareholders) and creditors of the Company.